OSR Health, Inc.
OOTC:OSRH0.20
USD
+0.00
(+2.14%)
OSR Health, Inc.
OTC:OSRH
(OTC Markets)
Recent
price
0.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- OSR Health, Inc. (OTC: OSRH) is a diversified healthcare and life sciences holding company engaged in the development, manufacture, and commercialization of biopharmaceutical therapeutics, aesthetic and reconstructive surgical devices, and advanced medical technologies. The company operates through two primary business segments: Biopharmaceuticals and Medical Devices. Its core product and service offerings comprise oral cancer immunotherapies and plasmid DNA vaccination platforms targeting tumor stroma and oncological antigens; medical-grade silicone breast, gluteal, and facial implants for aesthetic and reconstructive plastic surgery; surgical tissue expanders and specialty biomaterials; interventional medical supplies; and comprehensive clinical development, regulatory licensing, and cross-border commercial distribution services for biomedical technologies. OSR Health, Inc. serves hospital networks, specialized surgical centers, oncology research clinics, aesthetic practices, and healthcare distribution channels across North America, Europe, Latin America, and the Asia-Pacific region. Founded in 2019 and headquartered in Seoul, South Korea, with executive and clinical management offices in the United States and Switzerland, the company operates key international operating subsidiaries including Vaximm AG and Groupe Sebbin. In recent developments, OSR Health, Inc. finalized a comprehensive corporate reorganization and commenced trading on the OTC Markets under the ticker symbol OSRH to support the consolidation and scaling of its global life sciences assets. Over the past two years, the company expanded its clinical-stage immuno-oncology pipeline through targeted clinical trial advancements and strategic research collaborations, while simultaneously broadening regulatory market authorizations and third-party distribution partnerships for its medical aesthetic portfolio across high-growth Asian and European territories. Furthermore, OSR Health, Inc. secured strategic private equity placements and capital financing to accelerate ongoing clinical trials, enhance manufacturing infrastructure, and execute targeted strategic acquisitions in precision therapeutics and regenerative medical devices.